Pricing

Matrix Pharmaceutical Inc. (MATX)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
34700 CAMPUS DR FREMONT, CA 94555

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Are you looking for this stock instead?

Matrix Pharmaceutical, Inc. develops and manufactures novel drug product candidates for cancer based on its internal research and development capabilities and through in-licensing of product candidates from research institutions or other pharmaceutical companies. The Company's novel pharmaceutical product candidates are designed to improve the delivery of cancer drugs for more effective treatment of solid tumors. Two product candidates of the Company have been, or are being, evaluated in human clinical trials: IntraDose (cisplatin/epinephrine) Injectable Gel and MPI 5020 Radiopotentiator. The Company also in-licenses product candidates for development. In-licensed in 1998, tezacitabine (FMdC) is an intravenously administered therapeutic being developed for colorectal, hematologic and other cancers. The Company currently owns worldwide marketing rights for all its products under development, except for tezacitabine in Japan. In March 2002, the Company was acquired by Chiron Corporation.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available